1257426-19-9
Chemical Structure
TBA-354
- CAS No.: 1257426-19-9
- Formula:C19H15F3N4O5
- Molecular Weight:436.34
IUPAC Name: (S)-2-nitro-6-((6-(4-(trifluoromethoxy)phenyl)pyridin-3-yl)methoxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine
InChIKey: ZXSGSFMORAILEY-HNNXBMFYSA-N
SMILES: FC(F)(F)OC1=CC=C(C2=CC=C(CO[C@H]3CN4C(OC3)=NC([N+]([O-])=O)=C4)C=N2)C=C1
Biological Activity: TBA-354 is an orally active, blood-brain barrier permeable anti-tuberculosis compound. TBA-354 acts on replicating, non-replicating and drug-resistant Mycobacterium tuberculosis, retains its activity in the presence of serum proteins or albumin, and induces moderate, reversible neurotoxicity at effective dose levels. TBA-354 can be used in the research of tuberculosis and multidrug-resistant tuberculosis[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
TBA-354 | 99.74% | TBA-354 is an orally active, blood-brain barrier permeable anti-tuberculosis compound. TBA-354 acts on replicating, non-replicating and drug-resistant Mycobacterium tuberculosis, retains its activity in the presence of serum proteins or albumin, and induces moderate, reversible neurotoxicity at effective dose levels. TBA-354 can be used in the research of tuberculosis and multidrug-resistant tuberculosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
TBA-354 (Standard) | ≥98% | TBA-354 (Standard) is the analytical standard of TBA-354 (HY-12485). This product is intended for research and analytical applications. TBA-354 is an orally active, blood-brain barrier permeable anti-tuberculosis compound. TBA-354 acts on replicating, non-replicating and drug-resistant Mycobacterium tuberculosis, retains its activity in the presence of serum proteins or albumin, and induces moderate, reversible neurotoxicity at effective dose levels. TBA-354 can be used in the research of tuberculosis and multidrug-resistant tuberculosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Upton AM, et al. In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy. 2015 Jan;59(1):136-44. [Content Brief]
- [2]. Tasneen R, et al. Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis. Antimicrobial agents and chemotherapy. 2015 Jan;59(1):129-35. [Content Brief]
- [3]. Verma S, et al. Inhaled Adjunct Therapy with Second-Line Drug Candidates for Dose Reduction in Chemotherapeutic Regimens for Multi-drug-Resistant Tuberculosis. AAPS PharmSciTech. 2023 Jun 08;24(5):130.
Keywords
